TNFRSF14 and neoplasm: Mice with TNFRSF14 antibody treatment, especially the combination treatment group, exhibited significantly decreased tumor growth and lower ratio of Ki67 staining positive cells (Fig. 6I and Figure S7C-F) in tumor tissues compared to control group and anti-PD-L1 mono-treatment group, respectively.